Edition:
United States

BioLine RX Ltd (BLRX.TA)

BLRX.TA on Tel Aviv Stock Exchange

381.00
1 Dec 2016
Change (% chg)

-9.50₪ (-2.43%)
Prev Close
391.30₪
Open
390.00₪
Day's High
390.00₪
Day's Low
378.00₪
Volume
65,945
Avg. Vol
78,316
52-wk High
648.70₪
52-wk Low
287.50₪

BLRX.TA

Chart for BLRX.TA

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)
No analyst recommendations are available for BLRX.TA.

Overall

Beta: 0.23
Market Cap(Mil.): ₪244.90
Shares Outstanding(Mil.): 57.03
Dividend: --
Yield (%): --

Financials

  BLRX.TA Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.87 -- --
ROI: -25.76 -1.09 14.95
ROE: -26.49 -2.39 16.29

BRIEF-Biolinerx reports Q3 financial results

* Bioline RX Ltd - operating loss for three months ended September 30, 2016 amounted to $4.5 million versus operating loss of $3.6 million

Nov 22 2016

BRIEF-BioLine RX in-licenses novel anti-inflammatory treatment for dry eye syndrome under strategic collaboration with major global pharmaceutical company

* BioLine RX Ltd - in addition to des, biolinerx intends to explore potential use of bl-1230 in systemic inflammatory conditions

Nov 21 2016

BRIEF-Bioline RX discloses positive correlative data from phase 2A AML study

* Biolinerx discloses positive correlative data from phase 2a aml study and mechanism-of-action data for bl-8040 oncology platform at ash 2016

Nov 03 2016

BRIEF-Biolinerx announces initiation of Phase 2A trial of BL-8040 in combination with Keytruda

* Study will be conducted in us, israel and additional territories

Sep 20 2016

BRIEF-BioLineRx presents final results from Phase 2a trial for relapsed/refractory AML at SOHO conference

* BioLineRx presents final results from Phase 2a trial for relapsed/refractory AML at SOHO conference

Sep 08 2016

BRIEF-Bioline RX Ltd Q2 loss per share $0.07

* Qtrly loss per share $0.07 Source text for Eikon: Further company coverage:

Aug 11 2016

BRIEF-Bioline RX names Philip Serlin CEO

* Also appoints Mali Zeevi, as chief financial officer, effective october 10, 2016

Aug 11 2016

BRIEF-Biolinerx signs second clinical immuno-oncology collaboration agreement

* Biolinerx signs second clinical immuno-oncology collaboration agreement to investigate combination of bl-8040 and Keytruda for pancreatic cancer Source text for Eikon: Further company coverage:

Aug 08 2016

Earnings vs. Estimates